Testing ak112 for advanced lung cancer with gene changes after prior targeted therapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-squamous non-small cell lung cancer, and it is advanced (stage III or IV).
- You have a specific gene change (mutation) in your tumor, such as EGFR, ALK, ROS1, NTRK, RET, BRAF, or MET (confirmed by a test).
- You have already tried and failed a targeted therapy pill (a TKI) that was meant for your gene change.
- You have not received immunotherapy in the past, and you have not had other anti-cancer treatments for advanced disease other than targeted therapies.
- You have at least one tumor outside the brain that can be measured on scans, and you are generally feeling well enough to be active (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests two drugs, SHR-A1811 and AK112, for people with advanced non-small cell lung cancer that has HER2 changes. It may help if you have not improved on standard treatment or if you have not yet had treatment.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.